PMID- 33090916
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20220531
IS  - 2156-535X (Electronic)
IS  - 2156-5333 (Linking)
VI  - 10
IP  - 5
DP  - 2021 Oct
TI  - Hodgkin Lymphoma in Adolescent and Young Adults: Real-World Data from a Single 
      Tertiary Cancer Center in India.
PG  - 581-587
LID - 10.1089/jayao.2020.0061 [doi]
AB  - Purpose: There is lack of consensus on management of adolescent and young adult 
      (AYA) Hodgkin lymphoma with respect to chemotherapy approach (adult or 
      pediatric). Hence we sought to evaluate the efficacy and safety of Adriamycin, 
      Bleomycin, Vinblastine and Dacarbazine (ABVD) chemotherapy in AYA Hodgkin 
      lymphoma. Patients and Methods: It is a retrospective, observational, 
      single-center study. From January 2013 to December 2016, all consecutive patients 
      with AYA (15-25 years, all stages) were analyzed. The primary endpoint of the 
      study was event-free survival (EFS). Secondary endpoints were complete response 
      rates (CR) and overall survival (OS). Results: A total of 220 patients (70% men) 
      with median age 20 years were evaluated. A significant proportion of patients had 
      adverse features such as stage III/IV disease (63%), bulky disease (63%), 
      extranodal involvement (37%), and marrow involvement (22%). After two cycles and 
      end of therapy, 77% patients achieved complete response. Primary progressive 
      disease was seen in 6% patients. With a median follow-up of 2.6 years, 19 (8.6%) 
      patients relapsed, 1 patient developed second malignancy, and 6 patients died. 
      Three-year EFS and OS were 81.3% and 97%, respectively. Bleomycin-induced lung 
      injury was seen in 16% patients. On multivariate analysis stage at presentation, 
      bone marrow involvement, partial response at interim positron emission tomography 
      and International prognosis score (IPS) >3 were predictors of poor EFS. 
      Conclusion: ABVD is an effective and safe regimen in AYA Hodgkin lymphoma. 
      Advanced disease with high IPS (>3) score needs an early escalation approach to 
      escBEACOPP regimen.
FAU - Nayak, Lingaraj
AU  - Nayak L
AD  - Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Jain, Hasmukh
AU  - Jain H
AD  - Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Bonda, Avinash
AU  - Bonda A
AD  - Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Epari, Sridhar
AU  - Epari S
AD  - Department of Pathology, and Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Laskar, Siddhartha
AU  - Laskar S
AD  - Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Gokarn, Anant
AU  - Gokarn A
AD  - Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Shet, Tanuja
AU  - Shet T
AD  - Department of Pathology, and Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Gujral, Sumeet
AU  - Gujral S
AD  - Department of Pathology, and Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Khanna, Nehal
AU  - Khanna N
AD  - Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Bagal, Bhausaheb
AU  - Bagal B
AD  - Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Punatar, Sachin
AU  - Punatar S
AD  - Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Goda, Jayant
AU  - Goda J
AD  - Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Thorat, Jayashree
AU  - Thorat J
AD  - Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Rengaraj, Karthik
AU  - Rengaraj K
AD  - Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
FAU - Sengar, Manju
AU  - Sengar M
AD  - Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National 
      Institute, Mumbai, India.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20201022
PL  - United States
TA  - J Adolesc Young Adult Oncol
JT  - Journal of adolescent and young adult oncology
JID - 101543508
RN  - 11056-06-7 (Bleomycin)
RN  - 5J49Q6B70F (Vincristine)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bleomycin/therapeutic use
MH  - Child
MH  - Cyclophosphamide
MH  - Dacarbazine/therapeutic use
MH  - Doxorubicin/therapeutic use
MH  - Etoposide
MH  - Female
MH  - *Hodgkin Disease/drug therapy
MH  - Humans
MH  - Male
MH  - Prednisone/therapeutic use
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Vinblastine/therapeutic use
MH  - Vincristine/therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - ABVD
OT  - Hodgkin lymphoma
OT  - adolescent and young adult
EDAT- 2020/10/23 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/10/22 17:31
PHST- 2020/10/23 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
PHST- 2020/10/22 17:31 [entrez]
AID - 10.1089/jayao.2020.0061 [doi]
PST - ppublish
SO  - J Adolesc Young Adult Oncol. 2021 Oct;10(5):581-587. doi: 
      10.1089/jayao.2020.0061. Epub 2020 Oct 22.